Session » SLE – Treatment Poster III
- 10:30AM-12:30PM
-
Abstract Number: 2440
Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient’s Characteristics
- 10:30AM-12:30PM
-
Abstract Number: 2424
Anifrolumab Effects on Response to Influenza Vaccine in SLE
- 10:30AM-12:30PM
-
Abstract Number: 2427
Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Induces Multicompartmental B Cell Depletion in Peripheral Blood, Bone Marrow and Lymph Nodes of Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2437
Aryl Hydrocarbon Receptor as an Intrinsic Novel Checkpoint That Inhibits TLR7-induced B-cell Activation in SLE
- 10:30AM-12:30PM
-
Abstract Number: 2423
Associations Between Cytometric Interferon Signature and Clinical Response in a Cohort of Anifrolumab-treated Patients with Lupus
- 10:30AM-12:30PM
-
Abstract Number: 2435
Attainment of Remission, Use of Immunomodulatory/suppressive Agents and Gradual Dose Tapering May Facilitate Flare-free Withdrawal of Glucocorticoids in Patients with Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2436
Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2430
Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial
- 10:30AM-12:30PM
-
Abstract Number: 2422
Development of a Multiplexed-engineered, Off-the-shelf CAR NK Cell with Unique Multi-Pathogenic Cell Targeting Capacity for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
- 10:30AM-12:30PM
-
Abstract Number: 2431
DORIS Remission in Patients with SLE Treated with Anifrolumab: Post Hoc Analysis from TULIP-1 and TULIP-2 Trials in Patents with No Reported History of Prior Immunosuppressant Use
- 10:30AM-12:30PM
-
Abstract Number: 2434
ESK-001, an Allosteric TYK2 Inhibitor, Maximally Suppresses Type 1 Interferon, a Therapeutic Pathway Central to SLE and CLE
- 10:30AM-12:30PM
-
Abstract Number: 2425
Ianalumab Induced Durable Depletion of Circulating B Cell Subsets and Associated Changes in B Cell and Neutrophil Transcriptomic and Proteomic Profiles in Patients with Systemic Lupus Erythematosus: 52-Week Treatment Results from a Phase 2 Trial
- 10:30AM-12:30PM
-
Abstract Number: 2429
Impact of Hydroxychloroquine Level on ECG QTC Interval in Patients with Rheumatic Systemic Autoimmune Diseases: A Real-life Study
- 10:30AM-12:30PM
-
Abstract Number: 2432
In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist
- 10:30AM-12:30PM
-
Abstract Number: 2426
Multi-OMICs Analysis Including Lipidomics to Correlate Baseline OMICs Profiles with Disease Activity and Response to Different Immunomodulatory Treatments in Patients with Systemic Lupus Erythematosus – An Exploratory Pilot Study Using a Multi-OMICs Approach
- 10:30AM-12:30PM
-
Abstract Number: 2439
Preliminary Analysis of Open-Label Dose-Titration Phase of SLE Treatment with N-Acetylcysteine (SNAC) Shows Evidence for Potential Improvement of SLEDAI, BILAG, ADHD and Fatigue Scores in Patients with Active SLE
- 10:30AM-12:30PM
-
Abstract Number: 2438
Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 2433
Sequential Pneumococcal Vaccination in SLE: Immunogenicity, Side Effects and Comparison with PPSV23 Vaccination
- 10:30AM-12:30PM
-
Abstract Number: 2421
Trends in Glucocorticoid Use in Systemic Lupus Erythematosus in a Population-Based Inception Cohort from 1976 to 2018: The Lupus Midwest Network
- 10:30AM-12:30PM
-
Abstract Number: 2428
Vitamin-D Effect on SLE- Scoping Review